352 related articles for article (PubMed ID: 26045851)
1. Sarcomatous transformation of EGFR and TP53 mutation-positive metastatic adenocarcinoma of the lungs, masquerading as a primary pleomorphic sarcoma of the proximal femur.
Toda-Ishii M; Akaike K; Kurisaki-Arakawa A; Arakawa A; Mukaihara K; Suehara Y; Takagi T; Kaneko K; Yao T; Saito T
Int J Clin Exp Pathol; 2015; 8(3):3270-8. PubMed ID: 26045851
[TBL] [Abstract][Full Text] [Related]
2. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
Chang YL; Wu CT; Shih JY; Lee YC
Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
[TBL] [Abstract][Full Text] [Related]
3. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
4. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
5. Alteration of the p53 gene of lung carcinomas with sarcomatous transformation (spindle cell carcinoma): analysis of four cases.
Kawano R; Takeshima Y; Inai K
Pathol Int; 1996 Jan; 46(1):38-45. PubMed ID: 10846548
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
7. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
8. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.
Shingyoji M; Kageyama H; Sakaida T; Nakajima T; Matsui Y; Itakura M; Iuchi T; Yokoi S; Kimura H; Iizasa T
J Thorac Oncol; 2011 Jul; 6(7):1215-20. PubMed ID: 21610522
[TBL] [Abstract][Full Text] [Related]
9. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
Ushiki A; Koizumi T; Kobayashi N; Kanda S; Yasuo M; Yamamoto H; Kubo K; Aoyagi D; Nakayama J
Jpn J Clin Oncol; 2009 Apr; 39(4):267-70. PubMed ID: 19155283
[TBL] [Abstract][Full Text] [Related]
10. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
11. Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Chonan M; Narita N; Tominaga T
BMC Res Notes; 2016 Jan; 9():2. PubMed ID: 26724810
[TBL] [Abstract][Full Text] [Related]
12. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma.
Allo G; Bandarchi B; Yanagawa N; Wang A; Shih W; Xu J; Dalby M; Nitta H; To C; Liu N; Sykes J; Tsao MS
Histopathology; 2014 May; 64(6):826-39. PubMed ID: 24251405
[TBL] [Abstract][Full Text] [Related]
14. A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up.
Saito T; Mitomi H; Izumi H; Suehara Y; Okubo T; Torigoe T; Takagi T; Kaneko K; Sato K; Matsumoto T; Yao T
Hum Pathol; 2011 May; 42(5):727-33. PubMed ID: 21237496
[TBL] [Abstract][Full Text] [Related]
15. Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers.
Chang YL; Wu CT; Shih JY; Lee YC
Ann Surg Oncol; 2011 Feb; 18(2):543-50. PubMed ID: 20811949
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung.
Yoo SB; Chung JH; Lee HJ; Lee CT; Jheon S; Sung SW
J Thorac Oncol; 2010 Jul; 5(7):964-9. PubMed ID: 20512074
[TBL] [Abstract][Full Text] [Related]
17. Fibrosarcoma development 15 years after curettage and bone grafting of giant cell tumor of bone.
Li J; Zhu Y; Wei Y
Orthopedics; 2014 May; 37(5):e512-6. PubMed ID: 24810832
[TBL] [Abstract][Full Text] [Related]
18. A case of pulmonary adenocarcinoma with sarcomatous elements initially manifested as a submucosal tumor of the stomach.
Fukuda T; Ohnishi Y; Katagiri J; Ohnuki K; Tachikawa S
Acta Pathol Jpn; 1992 Jun; 42(6):454-9. PubMed ID: 1502906
[TBL] [Abstract][Full Text] [Related]
19. An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation.
Tsukamoto Y; Futani H; Kihara T; Watanabe T; Kumanishi S; Matsuo S; Hirota S; Ueda T; Yamamoto H; Yoshiya S
Pathol Res Pract; 2018 Sep; 214(9):1504-1509. PubMed ID: 29970305
[TBL] [Abstract][Full Text] [Related]
20. Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Weber B; Sorensen BS; Knap MM; Madsen HH; Nexo E; Meldgaard P
J Thorac Oncol; 2011 Nov; 6(11):1946-9. PubMed ID: 22005472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
